Table 6
Univariate analyses of RFS and BCS in patients without adjuvant tamoxifen treatment
| Variable | RFS | BCS | ||||||
|---|---|---|---|---|---|---|---|---|
| RR | 95% CI | p Value | RR | 95% CI | p Value | |||
| BCS, breast cancer survival; CI, confidence interval; IDC, invasive ductal carcinomas; ILC, invasive lobular carcinoma; NHG, Nottingham histological grade; RFS, recurrence free survival; RR, relative risk. | ||||||||
| Tumour type | ILC v IDC | 0.63 | 0.32 to 1.24 | 0.17 | 0.71 | 0.34 to 1.46 | 0.35 | |
| Ki-67 | 3 v 1+2 | 1.58 | 1.06 to 2.35 | 0.03 | 1.90 | 1.24 to 2.92 | 0.003 | |
| Mitotic index | 2+3 v 1 | 1.98 | 1.34 to 2.92 | 0.01 | 2.06 | 1.32 to 3.19 | 0.001 | |
| NHG | 3 v 1+2 | 1.82 | 1.30 to 2.54 | <0.001 | 2.42 | 1.67 to 3.53 | <0.001 | |
| Age | Continuous | 0.97 | 0.94 to 0.99 | 0.009 | 0.96 | 0.93 to 0.99 | 0.006 | |
| Node status | N+ v N0 | 1.97 | 1.29 to 3.02 | <0.01 | 2.21 | 1.35 to 3.61 | <0.01 | |
| Tumour size | T2 v T1 | 1.24 | 0.89 to 1.73 | 0.21 | 1.40 | 0.96 to 2.03 | 0.08 | |
